[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-343072-105":59,"doc-detail-343072-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","progress-of-lymphocyte-activation-gene-3-and-programmed-cell-death-protein-1-antibodies-for-cancer-treatment-a-review","Progress of lymphocyte activation gene 3 and programmed cell death protein 1 antibodies for cancer treatment - A review","","Immune checkpoint inhibitors (ICIs) have become an effective cancer treatment, with checkpoints including PD-1/PD-L1 and LAG-3 receiving extensive research attention. The review outlines the biological roles of PD-1 and LAG-3, then focuses on the combined use of PD-1 and LAG-3 antibodies in both in vivo and in vitro settings. It summarizes findings across T-cell expression/activation, toxicity assessment, melanoma (including MC38) and other tumor models, and relevant clinical studies in multiple solid cancers.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/progress-of-lymphocyte-activation-gene-3-and-programmed-cell-death-protein-1-antibodies-for-cancer-treatment-a-review/343072/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/progress-of-lymphocyte-activation-gene-3-and-programmed-cell-death-protein-1-antibodies-for-cancer-treatment-a-review/343072.png","ImageObject",300,407,{"name":92,"@type":93},"Ezra","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main focus of the review?","Question",{"text":112,"@type":113},"The review provides an overview of PD-1 and LAG-3 checkpoints and emphasizes the combined use of PD-1 and LAG-3 antibodies in both in vivo and in vitro studies, followed by clinical evaluation context.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which immune checkpoints are discussed as important targets in cancer immunotherapy?",{"text":117,"@type":113},"Key checkpoints include PD-1/PD-L1, CTLA-4, TIM-3, TIGIT, and LAG-3, with antibodies or inhibitors evaluated alone or in combination across tumor types.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the review evaluate the combined PD-1 and LAG-3 antibody strategy?",{"text":121,"@type":113},"It summarizes T-cell expression and activation correlations in vitro, assesses toxicity in animals for in vivo preparation, and reports effects across animal tumor models and in clinical studies.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},343072,1790824517,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","REVIEW  \nProgress of lymphocyte activation gene 3 and programmed cell death protein 1 antibodies for cancer treatment: A review  \nYu-Quan Li1, Xue-Mei Chen1, Gui-Fei Si1, and Xue-Min Yuan2 ∗  \nThe application of immune checkpoint inhibitors (ICIs) has proven to be an effective treatment for cancer. Immune checkpoints, such as programmed cell death protein 1/programmed cell death protein 1 ligand 1 (PD-1/PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), T-cell immunoglobulin-3 (TIM-3), T-cell immunoglobulin and ITIM domain (TIGIT), and lymphocyte activation gene 3 (LAG-3) have received extensive attention, and the efficacy of antibodies or inhibitors against these checkpoints (either alone or in combination) has been evaluated in many tumors. This paper provides a brief overview of the PD-1 and LAG-3 checkpoints and then shifts focus to the combined use of PD-1 and LAG-3 antibodies in both in vivo and in vitro experiments. In the in vitro experiments, we examined the correlation between the expression and activation of these inhibitors on T cells, and also assessed toxicity in animals in preparation for in vivo experiments. The effects of the combined use of PD-1 and LAG-3 antibodies were then summarized in animal models of melanoma, MC38 carcinoma, and other tumors. In clinical studies, the combined application of these antibodies was assessed in patients with melanoma, colorectal, breast, and renal cell cancers, as well as other solid tumors. In general, the combination of PD-1 and LAG-3 antibodies has shown promising results in both in vivo and in vitro studies.  \nKeywords: Immunotherapy, programmed cell death protein 1 (PD-1), programmed cell death protein 1 ligand 1 (PD-L1), lymphocyte activation gene 3 (LAG-3), combination therapy.  \nIntroduction  \nTreating cancer has long been a challenging task for humans. Advances in surgeries, radiotherapy, and chemotherapy have led to improved outcomes for many cancer patients. However, those with advanced cancer continue to face a poor prognosis. As our understanding of the immune system has deepened, researchers have explored using immune cells to target and eliminate cancer. This has sparked signiﬁcant interest in tumor immunotherapy [1] . One of the key research areas is immune checkpoints, such as programmed cell death protein 1 (PD-1), programmed cell death protein 1 ligand 1 (PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), lymphocyte activation gene-3 (LAG-3), T-cell immunoglobulin-3 (TIM-3), and T-cell immunoglobulin and ITIM domain (TIGIT) [2] . After a large number of studies and trials were conducted, antibodies against these immune checkpoints have been progressively developed, such as nivolumab, pembrolizumab, and ipilimumab, among other antibodies [1, 3], and these antibodies have achieved good results. However, there are still a considerable number of patients with a low response rate or serious adverse events (AEs) [1] .  \nTo enhance treatment eﬃcacy, researchers have introduced immune-based combination therapy, which involves  \ncombining immunotherapy with chemotherapy or tyrosine kinase inhibitors (TKIs) [4] . For example, some researchers treat renal cell carcinoma (RCC) with immune checkpoint inhibitors (ICIs) plus TKIs [5], while breast cancer is treated with ICIs plus ladiratuzumab (targeting LIV-1) [6] . Moreover, immune-based combinations or ICI monotherapy are being explored as adjuvant treatment for hepatocellular carcinoma (HCC) [7] . However, immune-based combination therapy is also thought to be associated with some AE, especially hypertransaminasemia [8] . Another option is to combine two diﬀerentICIs. Among them, the most concerning treatments are the combination of PD-1 and CTLA-4, and PD-1 and LAG-3 [1, 9] . The combined application of PD-1 and CTLA-4 antibodies was initiated at an early stage and has been widely used in clinical practice with a profound lasting response rate and controllable AEs, which has signiﬁcantly chang","cbCaimjaGqWTf80I","https://ap.wps.com/l/cbCaimjaGqWTf80I","pdf",1423866,11,"English","# Introduction\n# Immune checkpoints and rationale for combination therapy\n## PD-1/PD-L1 and LAG-3 in tumor immunotherapy\n## Limitations of current therapies and need for combination strategies\n# Review focus and experimental/clinical evidence","[{\"question\":\"What is the main focus of the review?\",\"answer\":\"The review provides an overview of PD-1 and LAG-3 checkpoints and emphasizes the combined use of PD-1 and LAG-3 antibodies in both in vivo and in vitro studies, followed by clinical evaluation context.\"},{\"question\":\"Which immune checkpoints are discussed as important targets in cancer immunotherapy?\",\"answer\":\"Key checkpoints include PD-1/PD-L1, CTLA-4, TIM-3, TIGIT, and LAG-3, with antibodies or inhibitors evaluated alone or in combination across tumor types.\"},{\"question\":\"How does the review evaluate the combined PD-1 and LAG-3 antibody strategy?\",\"answer\":\"It summarizes T-cell expression and activation correlations in vitro, assesses toxicity in animals for in vivo preparation, and reports effects across animal tumor models and in clinical studies.\"}]","Progress of lymphocyte activation gene 3 and programmed cell death protein 1 antibodies for cancer treatment - A review | PDF",1790049754,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4c7e01f8b8155be76f32d41e2aa02147.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ff9668db0e6fbe5bdb35069d0f99c727.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/69d751f00169ba31c17c1d860e8fe865.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4d8699192f15d909043796918eb1877a.webp",980,1268]